Articles by Anglia Ruskin University

First T-Cell Therapy Improves Survival in ARDS Patients

Phase 1/2 trial data suggest that iNKT-cell therapy reduced systemic inflammation and pneumonia risk in patients on VV-ECMO

The Cov2-ID qPCR test targets three viral genes instead of two, increasing reliability